TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Greco, Stephanie H ^a   Tomkötter, Lena ^a   Vahle, Anne Kristin ^a   Rokosh, Rae ^a   Avanzi, Antonina ^a   Mahmood, Syed Kashif ^a   Deutsch, Michael ^a   Alothman, Sara ^a   Alqunaibit, Dalia ^a   Ochi, Atsuo ^a   Zambirinis, Constantinos ^a   Mohaimin, Tasnima ^a   Rendon, Mauricio ^a   Levie, Elliot ^a   Pansari, Mridul ^a   Torres Hernandez, Alejandro ^a   Daley, Donnele ^a   Barilla, Rocky ^a   Pachter, H Leon ^a   Tippens, Daniel ^a   Malik, Hassan ^a   Boutajangout, Allal ^a   Wisniewski, Thomas ^a   Miller, George ^a   more..

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRS 954; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AFFECTING AGENT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA ANTIBODY 1D11.16.8; UNCLASSIFIED DRUG; ANTIBODY;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE MINERAL; CACHEXIA; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; EXPERIMENTAL BEHAVIORAL TEST; FAT MASS; LEAN BODY WEIGHT; MALE; MOUSE; MUSCLE ATROPHY; NONHUMAN; OBJECT RECOGNITION TEST; OVERALL SURVIVAL; PANCREAS CANCER; PERCENTAGE BODY FAT; PHARMACOLOGICAL BLOCKING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; ROTAROD TEST; VALIDATION STUDY; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METASTASIS; MORTALITY; PANCREAS TUMOR; PATHOLOGY; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; BODY COMPOSITION; CACHEXIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED C57BL; MUSCULAR ATROPHY; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84940703446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132786     Document Type: Article

References (68)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. Epub 2014/01/09. doi: 10.3322/caac.21208 PMID: 24399786.
2. Michaud DS. Epidemiology of pancreatic cancer. Minerva chirurgica. 2004; 59(2):99-111. Epub 2004/07/09. PMID: 15238885.
3. Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2011; 15(11):1917-27. Epub 2011/09/14. doi: 10.1007/s11605-011-1665-9 PMID: 21913044; PubMed Central PMCID: PMC3578347.
4. Bennani-Baiti N, Walsh D. Animal models of the cancer anorexia-cachexia syndrome. Support Care Cancer. 2011; 19(9):1451-63. Epub 2010/08/18. doi: 10.1007/s00520-010-0972-0 PMID: 20714754.
5. Argiles JM, Lopez-Soriano FJ, Busquets S. Mechanisms and treatment of cancer cachexia. Nutr Metab Cardiovasc Dis. 2012. Epub 2012/07/04. doi: S0939-4753(12)00121-4 [pii] doi: 10.1016/j.numecd.2012.04.011 PMID: 22749678.
6. Ronga I, Gallucci F, Riccardi F, Uomo G. Anorexia-cachexia syndrome in pancreatic cancer: recent advances and new pharmacological approach. Advances in medical sciences. 2014; 59(1):1-6. doi: 10.1016/j.advms.2013.11.001 PMID: 24797965.
7. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002; 52(2):72-91. Epub 2002/04/04. PMID: 11929007.
8. Biegler KA, Chaoul MA, Cohen L. Cancer, cognitive impairment, and meditation. Acta oncologica. 2009; 48(1):18-26. Epub 2008/11/26. doi: 10.1080/02841860802415535 PMID: 19031161.
9. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res. 1999; 59 (18):4493-501. Epub 1999/09/24. PMID: 10493494.
10. Lasheen W, Walsh D. The cancer anorexia-cachexia syndrome: myth or reality? Support Care Cancer. 2010; 18(2):265-72. Epub 2009/11/26. doi: 10.1007/s00520-009-0772-6 PMID: 19937260.
11. Ruiz Garcia V, Lopez-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. The Cochrane database of systematic reviews. 2013; 3:CD004310. Epub 2013/04/02. doi: 10.1002/14651858.CD004310.pub3 PMID: 23543530.
12. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage. 2004; 27(4):360-9. Epub 2004/03/31. doi: 10.1016/j.jpainsymman.2003.09.007 PMID: 15050664.
13. Lesniak W, Bala M, Jaeschke R, Krzakowski M. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome - a systematic review and meta-analysis. Pol Arch Med Wewn. 2008; 118(11):636-44. Epub 2009/01/15. PMID: 19140567.
14. Deboer MD. Animal models of anorexia and cachexia. Expert Opin Drug Discov. 2009; 4(11):1145-55. Epub 2010/02/18. doi: 10.1517/17460440903300842 PMID: 20160874; PubMed Central PMCID: PMC2771941.
15. Capella G, Farre L, Villanueva A, Reyes G, Garcia C, Tarafa G, et al. Orthotopic models of human pancreatic cancer. Ann N Y Acad Sci. 1999; 880:103-9. PMID: 10415855.
16. Grippo PJ, Sandgren EP. Modeling pancreatic cancer in animals to address specific hypotheses. Methods in molecular medicine. 2005; 103:217-43. PMID: 15542910.
17. Jones-Bolin S, Ruggeri B. Orthotopic model of human pancreatic ductal adenocarcinoma and cancer cachexia in nude mice. Curr Protoc Pharmacol. 2007;Chapter 14:Unit 14 3. Epub 2007/06/01. doi: 10.1002/0471141755.ph1403s37 PMID: 21948162.
18. Hotz HG, Reber HA, Hotz B, Yu T, Foitzik T, Buhr HJ, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas. 2003; 26(4):e89-98. Epub 2003/04/30. PMID: 12717279.
19. Akira S, Takeda K. Toll-like receptor signalling. Nature reviews Immunology. 2004; 4(7):499-511. doi: 10.1038/nri1391 PMID: 15229469.
20. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007; 81 (1):1-5. Epub 2006/10/13. doi: jlb.0306164 [pii] doi: 10.1189/jlb.0306164 PMID: 17032697.
21. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373-84. Epub 2010/04/21. doi: ni.1863 [pii] doi: 10.1038/ni.1863 PMID: 20404851.
22. Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. The Journal of clinical investigation. 2012; 122 (11):4118-29. doi: 10.1172/JCI63606 PMID: 23023703; PubMed Central PMCID: PMC3484447.
23. Wu HQ, Wang B, Zhu SK, Tian Y, Zhang JH, Wu HS. Effects of CPG ODN on biological behavior of PANC-1 and expression of TLR9 in pancreatic cancer. World J Gastroenterol. 2011; 17(8):996-1003. Epub 2011/03/31. doi: 10.3748/wjg.v17.i8.996 PMID: 21448350; PubMed Central PMCID: PMC3057161.
24. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nature reviews Cancer. 2010; 10(6):415-24. doi: 10.1038/nrc2853 PMID: 20495575.
25. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunology letters. 2002; 82(1-2):85-91. PMID: 12008039.
26. Truty MJ, Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology: official journal of the International Association of Pancreatology. 2007; 7(5-6):423-35. Epub 2007/09/28. doi: 10.1159/000108959 PMID: 17898532.
27. Hezel AF, Deshpande V, Zimmerman SM, Contino G, Alagesan B, O'Dell MR, et al. TGF-beta and alphavbeta6 integrin act in a common pathway to suppress pancreatic cancer progression. Cancer Res. 2012; 72(18):4840-5. doi: 10.1158/0008-5472.CAN-12-0634 PMID: 22787119; PubMed Central PMCID: PMC3764481.
28. Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, et al. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Molecular pharmacology. 2007; 72(1):152-61. doi: 10.1124/mol.106.029025 PMID: 17400764.
29. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes &development. 2006; 20(22):3130-46. Epub 2006/11/23. doi: 10.1101/gad.1478706 PMID: 17114584; PubMed Central PMCID: PMC1635148.
30. Zugmaier G, Paik S, Wilding G, Knabbe C, Bano M, Lupu R, et al. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res. 1991; 51(13):3590-4. PMID: 2054795.
31. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nature medicine. 2007; 13(11):1333-40. doi: 10.1038/nm1677 PMID: 17982462.
32. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. doi: 10.1126/science.1171362 PMID: 19460966; PubMed Central PMCID: PMC2998180.
33. Bedrosian AS, Nguyen AH, Hackman M, Connolly MK, Malhotra A, Ibrahim J, et al. Dendritic cells promote pancreatic viability in mice with acute pancreatitis. Gastroenterology. 2011; 141(5):1915-26 e1-14. doi: 10.1053/j.gastro.2011.07.033 PMID: 21801698; PubMed Central PMCID: PMC3202684.
34. Rao R, Graffeo CS, Gulati R, Jamal M, Narayan S, Zambirinis CP, et al. Interleukin 17-producing gammadeltaT cells promote hepatic regeneration in mice. Gastroenterology. 2014; 147(2):473-84 e2. doi: 10.1053/j.gastro.2014.04.042 PMID: 24801349; PubMed Central PMCID: PMC4123443.
35. Boutajangout A, Li YS, Quartermain D, Sigurdsson EM. Cognitive and sensorimotor tasks for assessing functional impairments in mouse models of Alzheimer's disease and related disorders. Methods in molecular biology. 2012; 849:529-40. doi: 10.1007/978-1-61779-551-0-35 PMID: 22528113; PubMed Central PMCID: PMC3859369.
36. SEER Cancer Statistics Review, 1975-2011 [Internet]. National Cancer Institute. Bethesda, MD. 2014.
37. Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, et al. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Frontiers in physiology. 2014; 5:88. Epub 2014/03/14. doi: 10.3389/fphys.2014.00088 PMID: 24624094; PubMed Central PMCID: PMC3939686.
38. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009; 15(22):6973-9. Epub 2009/11/06. doi: 10.1158/1078-0432.CCR-09-1525 PMID: 19887488.
39. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547):1704-8. doi: 10.1126/science.1065874 PMID: 11679633.
40. Amirouche A, Durieux AC, Banzet S, Koulmann N, Bonnefoy R, Mouret C, et al. Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology. 2009; 150(1):286-94. doi: 10.1210/en.2008-0959 PMID: 18801898.
41. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, et al. Induction of cachexia in mice by systemically administered myostatin. Science. 2002; 296(5572):1486-8. Epub 2002/05/25. doi: 10.1126/science.1069525 PMID: 12029139.
42. Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, et al. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 2013; 108(10):2063-9. Epub 2013/04/18. doi: 10.1038/bjc.2013.174 PMID: 23591198; PubMed Central PMCID: PMC3670479.
43. Bennani-Baiti N, Davis MP. Cytokines and cancer anorexia cachexia syndrome. Am J Hosp Palliat Care. 2008; 25(5):407-11. Epub 2008/04/12. doi: 1049909108315518 [pii] doi: 10.1177/1049909108315518 PMID: 18403577.
44. Zambirinis CP, Ochi A, Barilla R, Greco S, Deutsch M, Miller G. Induction of TRIF- or MYD88-dependent pathways perturbs cell cycle regulation in pancreatic cancer. Cell cycle. 2013; 12(8):1153-4. Epub 2013/04/04. doi: 10.4161/cc.24488 PMID: 23549168; PubMed Central PMCID: PMC3674074.
45. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. European journal of immunology. 2007; 37(12):3582-6. Epub 2007/11/24. doi: 10.1002/eji.200737815 PMID: 18034431.
46. Wakefield LM, Hill CS. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nature reviews Cancer. 2013; 13(5):328-41. Epub 2013/04/25. doi: 10.1038/nrc3500 PMID: 23612460.
47. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010; 142(4):531-43. doi: 10.1016/j.cell.2010.07.011 PMID: 20723755.
48. Loiselle C, Rockhill J. Radiation, chemotherapy, and symptom management in cancer-related cognitive dysfunction. Curr Pain Headache Rep. 2009; 13(4):271-6. PMID: 19586589.
49. Vaz J, Andersson R. Intervention on toll-like receptors in pancreatic cancer. World J Gastroenterol. 2014; 20(19):5808-17. Epub 2014/06/11. doi: 10.3748/wjg.v20.i19.5808 PMID: 24914341; PubMed Central PMCID: PMC4024790.
50. Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. The Journal of experimental medicine. 2012; 209(9):1671-87. doi: 10.1084/jem.20111706 PMID: 22908323; PubMed Central PMCID: PMC3428946.
51. Ramos EJ, Suzuki S, Marks D, Inui A, Asakawa A, Meguid MM. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides. Curr Opin Clin Nutr Metab Care. 2004; 7(4):427-34. Epub 2004/06/12. doi: 00075197-200407000-00012 [pii]. PMID: 15192446.
52. Patra SK, Arora S. Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome. Clin Chim Acta. 2012; 413(13-14):1025-34. Epub 2012/01/19. doi: S0009-8981(11)00672-3 [pii] doi: 10.1016/j.cca.2011.12.008 PMID: 22251421.
53. Zhang D, Zhou Y, Wu L, Wang S, Zheng H, Yu B, et al. Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer. Annals of clinical and laboratory science. 2008; 38(2):113-9. Epub 2008/05/13. PMID: 18469355.
54. Banduseela V, Ochala J, Lamberg K, Kalimo H, Larsson L. Muscle paralysis and myosin loss in a patient with cancer cachexia. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology / edited by the Gaetano Conte Academy for the study of striated muscle diseases. 2007; 26(3):136-44. PMID: 18646562; PubMed Central PMCID: PMC2949304.
55. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology. 2000; 14(1):75-9; discussion 9, 81-2, 5. PMID: 10680150.
56. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A. 1995; 92(12):5545-9. PMID: 7777546; PubMed Central PMCID: PMC41732.
57. Simeone DM, Pham T, Logsdon CD. Disruption of TGFbeta signaling pathways in human pancreatic cancer cells. Annals of surgery. 2000; 232(1):73-80. PMID: 10862198; PubMed Central PMCID: PMC1421110.
58. Javle M, Li Y, Tan D, Dong X, Chang P, Kar S, et al. Biomarkers of TGF-beta signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014; 9(1):e85942. doi: 10.1371/journal.pone.0085942 PMID: 24465802; PubMed Central PMCID: PMC3896410.
59. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-beta: duality of function between tumor prevention and carcinogenesis. Journal of the National Cancer Institute. 2014; 106(2):djt369. doi: 10.1093/jnci/djt369 PMID: 24511106; PubMed Central PMCID: PMC3952197.
60. Jacobs EJ, Newton CC, Silverman DT, Nogueira LM, Albanes D, Mannisto S, et al. Serum transforming growth factor-beta1 and risk of pancreatic cancer in three prospective cohort studies. Cancer causes &control: CCC. 2014; 25(9):1083-91. Epub 2014/06/11. doi: 10.1007/s10552-014-0409-z PMID: 24913781.
61. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008; 7(4):829-40. Epub 2008/04/17. doi: 10.1158/1535-7163.MCT-07-0337 PMID: 18413796; PubMed Central PMCID: PMC3088432.
62. Kim YJ, Hwang JS, Hong YB, Bae I, Seong YS. Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Res. 2012; 32(3):799-806. Epub 2012/03/09. PMID: 22399597; PubMed Central PMCID: PMC3508670.
63. Mendias CL, Gumucio JP, Davis ME, Bromley CW, Davis CS, Brooks SV. Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle & nerve. 2012; 45(1):55-9. doi: 10.1002/mus.22232 PMID: 22190307; PubMed Central PMCID: PMC3245632.
64. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci U S A. 1994; 91(19):8817-21. Epub 1994/09/13. PMID: 8090730; PubMed Central PMCID: PMC44697.
65. Gumucio JP, Mendias CL. Atrogin-1, MuRF-1, and sarcopenia. Endocrine. 2013; 43(1):12-21. doi: 10.1007/s12020-012-9751-7 PMID: 22815045; PubMed Central PMCID: PMC3586538.
66. Sartori R, Milan G, Patron M, Mammucari C, Blaauw B, Abraham R, et al. Smad2 and 3 transcription factors control muscle mass in adulthood. American journal of physiology Cell physiology. 2009; 296 (6):C1248-57. doi: 10.1152/ajpcell.00104.2009 PMID: 19357234.
67. Welle SL. Myostatin and muscle fiber size. Focus on "Smad2 and 3 transcription factors control muscle mass in adulthood" and "Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size". American journal of physiology Cell physiology. 2009; 296(6):C1245-7. doi: 10.1152/ajpcell.00154.2009 PMID: 19357232.
68. Kollias HD, McDermott JC. Transforming growth factor-beta and myostatin signaling in skeletal muscle. Journal of applied physiology. 2008; 104(3):579-87. doi: 10.1152/japplphysiol.01091.2007 PMID: 18032576.